Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that.
A follow-up question about orforglipron phase 2 that I did not know to ask the first time.
The earlier thread answered what I asked. What I should have asked is below, and I think it is the one that matters.
The opening post describes the usual case. This is about the unusual one.
I keep a log for orforglipron phase 2 specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.
Adding the boring version of orforglipron phase 2, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Confirming post #4 from a second method, which matters more than confirming it from a second person.
The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
I am describing what is, rather than arguing for what should be.
Before the thread moves on from orforglipron phase 2 — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Small correction to my own earlier position on orforglipron phase 2. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
This is the first time the answer has come with its own limits attached. Appreciated.
Worth separating two things that post #9 runs together.
Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
Adding it in case it saves somebody the afternoon it cost me.
Adding a data point of agreement rather than a data point.
I would put moderate confidence on the mainstream reading of orforglipron phase 2 and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
The claim is narrower than it sounds, and deliberately so.
Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.
Taking post #13 at face value and following it one step further.
On orforglipron phase 2: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
My experience of orforglipron phase 2 contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.
Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?
Adding the measurement that post #18 says would settle it.
What would change my mind on orforglipron phase 2 is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Noted, and thank you for writing it out rather than summarising it.
TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
I have separated what I observed from what I concluded, which does not always happen.
Source for the orforglipron phase 2 figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.
Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.
On post #24 — agreed on the reasoning, with one qualification.
I disagree with the framing of orforglipron phase 2 above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Orforglipron phase 2 is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Agreed on all of that, and I have nothing to add to it.
Two things can be true about orforglipron phase 2 at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.